Avidity del-zota data ‘highly encouraging,’ says Cantor Fitzgerald

Avidity’s first look at functional data from del-zota, its TfR-targeted exon skipper, in Duchenne Muscular Dystrophy exon 44 are “highly supportive” of del-zota’s first- and best-in-class potential in DMD44, Cantor Fitzgerald analyst Eric Schmidt tells investors in a research note. The firm, which has an Overweight rating and $96 price target on the shares, is “highly encouraged” by del-zota’s ability to consistently improve function across of range of endpoints.